Answers are grounded in this paper and cite their sources.
Around 2008 synthetic cannabinoids were found to be present in and responsible for the psychoactive effects of herbal mixtures with names like ‘Spice’ or ‘K2’. In response to the increased popularity of these products, (inter)national organizations and governments started banning these cannabimimetics gradually. However, the lack of an uniform and international regulation makes it hard to control this issue. For the different types of synthetic cannabinoids the scientific knowledge in terms of pharmacokinetics and pharmacodynamics is limited. This also means that little is known on the health of users, both on short and long term. In the last years effort has been made to make detection of these products possible in different biological matrices. However, since the number of cannabimimetic compounds on the market appears to grow every month, both scientist and legislators run after a moving target.
No takes yet. Share an insight, caveat, or question.
Brabanter et al. (2013) studied this question.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: